组织蛋白酶K抑制剂Odanacatib治疗骨质疏松的研究进展

Advances in Cathepsin K inhibitor Odanacatib in treatment of osteoporosis

组织蛋白酶K(cathepsin K,Cat K)为表达于破骨细胞的一种半胱氨酸蛋白酶,是骨重建过程中骨吸收的关键酶。相关研究证实,抑制其活性是治疗骨质疏松的一个新思路。当前最新研发的组织蛋白酶K抑制剂Odanacatib(ODN),可有效抑制骨的吸收且不抑制骨的形成,耐受性好,无明显的药物相关不良反应,为治疗骨质疏松提供了新的选择。

Cathepsin K （Cat K） is a cysteine protease expressed in osteoclasts, which is the key enzyme of bone resorption in the process of bone rebuilding. Related research confirms that inhibiting its activity is a new way for the treatment of osteoporosis. As the latest research and development of cathepsin K inhibitor, Odanacatib （ODN） can effectively inhibit bone absorption without inhibiting bone formation, and it also shows well tolerance and no obvious drug related adverse reaction, which provides a new option for treatment of osteoporosis.